Additionally, Shikonin treatments resulted in diminished levels of glioma stem cell markers (SOX2, CD44, CHI3L1, and CD24) and the BMDM-derived TAM marker CD49D in glioma cells and subcutaneous animal models. This evidence concerns the gene SOX2 and glioma.